Covid19NanoCOATNCT04717024
The Nanowear Wearable Covid-19 Observational and Analysis Trend
An observational study of Covid19, run by Nanowear Inc. at 2 sites in United States.
Trial summary
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid19
- Type of treatment
- Medical device
- How many people
- 15 participants
- Where
- 2 sitesUnited States
- Study dates
- 15 Sep 2020to 30 Apr 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects of legal age to give informed consent who are currently or recently hospitalized with a primary diagnosis of Covid-19
Who may be able to join
- Subject has provided informed consent
- Male or female over the age of 18 years
- The patient is currently hospitalized with a primary diagnosis of Covid-19
Who cannot join
- Subject is unwilling or unable to wear the vest during hospitalization.
- Subjects who are pregnant.
- Subject is intubated or admitted to ICU
- Subject has an implantable cardiac device (i.e pacemaker or internal cardioverter defibrillator)
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Maimonides Medical Center
Brooklyn, New York, 11219
Hackensack University Medical Center
Hackensack, New Jersey, 07601
About this study
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.
- Conditions
- Covid19
- Being tested
- Observational Study - no intervention
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational Study - no interventionDevice
Observational Study - no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Hosptialized patient data
The primary study endpoint is adequate collection of hospitalized COVID 19 patient health metric data through the Nanowear WMDRS
Measured: up to 30 days of monitoring leading to discharge or admission to ICU
Secondary outcomes (1)
Trends in COVID 19 exacerbation
Exploratory information will be used to compare the signals obtained from the device to the severity of Covid-19 as measured by clinical evaluation
Measured: up to 30 days of monitoring leading to discharge or admission to ICU
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2021
- Study start15 Sep 2020
- Primary completion15 Apr 2021
- Study completion30 Apr 2021
Why it stopped: Logistics and low enrollment.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nanowear Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04717024
- Sponsor's protocol ID
- NWCT20-SS-002
- Acronym
- NanoCOAT
- Status last verified
- Apr 2026
- First submitted
- 19 Jan 2021
- Last updated
- 9 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Nanowear Wearable Covid-19 Observational and Analysis Trend
- ClinicalTrials.gov ID
- NCT04717024
- Acronym / sponsor ID
- NanoCOAT / NWCT20-SS-002
- Conditions
- Covid19
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Logistics and low enrollment.
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Nanowear Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Sep 2020 (actual)
- Primary completion
- 15 Apr 2021 (actual)
- Study completion
- 30 Apr 2021 (actual)
- First posted
- 20 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects of legal age to give informed consent who are currently or recently hospitalized with a primary diagnosis of Covid-19
Key inclusion criteria (3 listed)
- Subject has provided informed consent
- Male or female over the age of 18 years
- The patient is currently hospitalized with a primary diagnosis of Covid-19
Key exclusion criteria (4 listed)
- Subject is unwilling or unable to wear the vest during hospitalization.
- Subjects who are pregnant.
- Subject is intubated or admitted to ICU
- Subject has an implantable cardiac device (i.e pacemaker or internal cardioverter defibrillator)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational Study - no interventionObservational Study - no intervention | Device | – |
Primary outcome
Hosptialized patient data
Time frame: up to 30 days of monitoring leading to discharge or admission to ICU
The primary study endpoint is adequate collection of hospitalized COVID 19 patient health metric data through the Nanowear WMDRS
1 secondary outcome
Trends in COVID 19 exacerbation
Time frame: up to 30 days of monitoring leading to discharge or admission to ICU
Results and safety
The study was stopped early (reason given: Logistics and low enrollment.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by Nanowear Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Logistics and low enrollment.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hosptialized patient data (time frame: up to 30 days of monitoring leading to discharge or admission to ICU). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026; AzTrials last refreshed its copy on 6 Nov 2026.